{
    "clinical_study": {
        "@rank": "154666", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo"
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase 1, single-blind, randomized, placebo-controlled, multiple ascending dose\n      study aimed to assess the safety, tolerability, and pharmacokinetics of GS-6615 in healthy\n      subjects."
        }, 
        "brief_title": "A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Ischemic Heart Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Heart Diseases", 
                "Ischemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Weight of at least 50 kg with body mass index (BMI) between 18 and 30 kg/m2\n\n          -  Female subjects must be of non-childbearing potential as defined per the protocol\n\n          -  Male subjects with female partners of childbearing potential must be using protocol\n             acceptable methods of contraception\n\n          -  Willing and able to comply with the requirements of the protocol and directions\n\n          -  Willing to avoid consumption of grapefruit, grapefruit juice and Seville oranges\n\n          -  Willing to avoid consumption of nicotine (including nicotine gum) and alcoholic\n             beverages\n\n        Exclusion Criteria:\n\n          -  Ongoing or history of any medical or surgical condition that, in the judgment of the\n             Investigator, might jeopardize the subject's safety or interfere with the study\n             objectives\n\n          -  History of meningitis or encephalitis, seizures, migraines, tremors, myoclonic jerks,\n             sleep disorder, anxiety, syncope, head injuries or a family history of seizures\n\n          -  Any abnormal ECG findings, abnormal laboratory value, or physical examination\n             findings at Screening judged to be clinically significant\n\n          -  Any abnormal neurological examination findings at Screening that is judged as\n             clinically significant\n\n          -  Hemoglobin < 12 g/dL\n\n          -  Serology test positive for HIV, or hepatitis B or C\n\n          -  Positive urine drug test (including cotinine or ethanol)\n\n          -  Use of systemic prescription medications or over the counter (OTC) medication,\n             including multivitamins, and dietary and herbal supplement\n\n          -  Use of any experimental or investigational drug or device within 30 days\n\n          -  Female subjects who are of childbearing potential, pregnant or lactating\n\n          -  Donation or loss of blood within 8 weeks and/or donation of plasma within 7 days\n\n          -  History of drug or alcohol abuse\n\n          -  Psychosocial or addictive disorders"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847391", 
            "org_study_id": "GS-US-279-0102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3"
                ], 
                "description": "GS-6615 tablet(s) administered orally once daily", 
                "intervention_name": "GS-6615", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3"
                ], 
                "description": "Placebo tablet(s) to match GS-6615 administered orally once daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Ischemic Heart Disease", 
            "Heart Disease"
        ], 
        "lastchanged_date": "November 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }, 
                "name": "Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Elizabeth Layug, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The primary outcome measure is the safety and tolerability of GS-6615 including neurological findings, adverse events, clinical laboratory tests, vital signs and ECG data (PR, RR, QRS, QT, and QTc [Fridericia] interval).", 
                "measure": "Safety and tolerability of GS-6615", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 65 days"
            }, 
            {
                "description": "The primary outcome measure is the PK profile of GS-6615 which will be measured with Cmax, Tmax, AUCtau, AUC0-\u221e, T1/2, CL/F, VSS/F, and R.", 
                "measure": "Pharmacokinetic (PK) profile of GS-6615", 
                "safety_issue": "No", 
                "time_frame": "Up to 65 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847391"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}